Medical/Pharmaceuticals
Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology
FUKUOKA, Japan, April 25, 2025 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, Japan) is pleased to announce that a research paper on the results of a joint study with the research group led by ProfessorMasayuki Nakamori of the Department of Neurology of the Yamaguchi University Graduate ...
2025-04-25 14:00
2149
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program
* Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundatio...
2025-04-25 12:01
2324
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CD...
2025-04-25 11:37
2323
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
HONG KONG, April 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabin...
2025-04-25 08:15
2580
A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia
PETALING JAYA, Malaysia, April 25, 2025 /PRNewswire/ -- In a landmark move to safeguard the vision ofMalaysia's future generation, VISTA Eye Specialist ('VISTA'), the nation's trusted eye care brand, announced a strategic collaborationMemorandum of Understanding (MoU) with EssilorLuxottica, the ...
2025-04-25 08:00
2781
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
* VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA) in treating NIAU * Clinically meaningful reductions in inflammation compared to baseline ...
2025-04-25 00:00
2671
Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics
SEOUL, South Korea, April 24, 2025 /PRNewswire/ -- Medit, a global leader in
digital dentistry solutions, and Graphy, a leading innovator in 3D printing
dental materials, have officially announced a strategic partnership to
accelerate advancements in the digital orthodontics market.
2025-04-25 00:00
3244
Primo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement ...
2025-04-24 23:00
2441
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
SHANGHAI, April 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that thePhase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced...
2025-04-24 20:00
2300
Sengkang General Hospital Introduces Siemens Healthineers Photon-Counting CT Scanner to Advance Diagnostic Capabilities
* New photon-counting CT scanner aims to enhance diagnostic imaging capabilities for SKH. * Advanced technology provides clearer images with lower radiation dose, improving diagnostic precision and patient safety. SINGAPORE, April 24, 2025 /PRNewswire/ --Sengkang General Hospital (SKH) offici...
2025-04-24 18:57
2769
Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025
* DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors and BTK degraders was selected for oral presentation ...
2025-04-24 18:38
2333
OMRON Healthcare Donates 4,000 Blood Pressure Monitors and Advances AFib Screening with AI-based Intellisense AFib Technology
- Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May17 Marks World Hypertension Day during May Measurement Month - KYOTO, Japan, April 24, 2025 /PRNewswire/ -- OMRON Healthcare Co., Ltd. (Head Office: Muko,Kyoto Prefecture; hereinafter referred t...
2025-04-24 16:00
2132
Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating
Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health" or "the Company", Stock Code: 1833.HK) announced its first-quarter results for...
2025-04-24 15:30
3601
SWS Medical and Hemotek - Partners in Innovations at the 45th Philippine Society of Nephrology Annual Convention
MANILA, Philippines, April 24, 2025 /PRNewswire/ -- SWS Medical, a leading Chinese blood purification provider, is excited to participate in the 45th Philippine Society of Nephrology Annual Convention (April 24-26, 2025 Preferred Booth 1),the Philippines' largest nephrology academic event. In par...
2025-04-24 14:57
2709
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis - - MM-II recently granted Fast Track Designation ...
2025-04-24 14:31
2258
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 30 to June 3. Resu...
2025-04-24 13:17
2290
Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hem...
2025-04-24 10:26
2452
2025 Medtec Free Pre-Registration Kicks Off! Meet Over 1000 Chinese Local Enterprises
SHANGHAI, April 24, 2025 /PRNewswire/ -- The 2025 Medtec International Medical Device Design & Manufacturing Technology Exhibition (hereinafter referred to as 2025 Medtec) will be held at the Halls 1&2 of Shanghai World Expo Exhibition & Convention Center fromSeptember 24 to September 26. This ex...
2025-04-24 09:00
1238
Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU,China, April 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2025-04-24 07:00
3591
CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry
- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion - Positioned for global expansion in $750M spinal bone graft market SEOUL, South Korea, April 23, 2025 /PRNewswire/ -- CGBIO(CEO Hyun Seung Yu), a leading Korean company specializing...
2025-04-24 00:00
2881
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 304 media titles]
2026-01-27 13:00
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
